Alkaline Epinephrine Formulation for Low-Impurity Shelf Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current epinephrine-containing pharmaceutical compositions face limitations such as short shelf life due to the formation of degradants like epinephrine sulfonic acid and D-epinephrine, leading to high impurity levels and reduced effectiveness.
Innovation Solution
A pharmaceutical composition comprising epinephrine with additives such as pH raising agents, antioxidants, transition metal complexing agents, pH lowering agents, and tonicity regulating agents to stabilize the formulation and reduce impurities, including low levels of D-epinephrine and epinephrine sulfonic acid, while maintaining pH stability over shelf life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If epinephrine is formulated in conventional pharmaceutical compositions, then it provides therapeutic effects for emergency treatments, but it forms degradants like epinephrine sulfonic acid and D-epinephrine leading to short shelf life and high impurity levels
Solution Approach 1:
The patent introduces pH raising agents (such as tromethamine, triethanolamine, or diethanolamine) as intermediary substances that mediate between epinephrine and its degradants. These agents maintain the formulation pH above 7.0, which interferes with the degradation pathway that produces epinephrine sulfonic acid and D-epinephrine, thereby extending shelf life while preserving therapeutic effectiveness.
Solution Approach 2:
The patent fundamentally changes the pH parameter of the epinephrine formulation from conventional acidic or neutral ranges to an alkaline range (pH > 7.0). This parameter change alters the chemical stability profile of epinephrine, reducing the formation of degradants and extending shelf life from months to years, while the epinephrine remains therapeutically effective.
2Quantity of substance
If epinephrine is stored in conventional formulations, then it maintains initial potency, but impurity levels increase over time reducing effectiveness
Solution Approach 1:
The patent converts the harmful effect of alkaline pH (which could potentially increase epinephrine reactivity) into a beneficial effect by selecting specific pH raising agents that maintain pH > 7.0 while actually reducing degradant formation. The alkaline environment prevents the formation of epinephrine sulfonic acid and D-epinephrine, turning a potentially harmful condition into a protective one that reduces impurity levels.
Solution Approach 2:
The pH raising agents act as intermediary substances that protect epinephrine from degradation. These agents (tromethamine, triethanolamine, or diethanolamine) intervene in the degradation pathway, maintaining a pH environment that prevents the formation of harmful degradants, thereby keeping impurity levels low while preserving epinephrine potency.
3Speed
If conventional epinephrine formulations are used, then they provide immediate therapeutic action, but require frequent replacement due to short shelf life
Solution Approach 1:
The patent performs preliminary action by establishing a stable alkaline pH environment (> 7.0) during formulation that prevents degradant formation before storage begins. This preliminary stabilization ensures that epinephrine remains potent throughout extended storage periods, reducing the need for frequent replacement while maintaining the capability for immediate therapeutic action when needed.
Solution Approach 2:
The patent changes the pH parameter to an alkaline range (> 7.0) that fundamentally alters the stability profile of epinephrine. This parameter change extends shelf life from months to years, reducing replacement frequency, while the epinephrine retains its ability to act rapidly when administered for emergency treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves extended shelf life with reduced impurity levels, improved stability, and enhanced effectiveness for emergency treatments and medical applications.
Implementation Method 1
The concentration of oxidative degradants present in the composition after a period of shelf life may be reduced by the antioxidant
Implementation Method 2
The composition may comprise a pH raising agent and/or a pH lowering agent
Implementation Method 3
The composition may comprise a transition metal complexing agent
Data Source
AI summary
Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.